Effects on the pharmacokinetics of L-DOPA formulation by Proton pump inhibitors in patients with Parkinson's disease
Phase 3
- Conditions
- Parkinson's disease
- Registration Number
- JPRN-UMIN000022529
- Lead Sponsor
- tano National Hospital, National Hospital Organization
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 8
Inclusion Criteria
Not provided
Exclusion Criteria
1.Patients who can't take tablets and capsules 2.Patients after gastrectomy 3.Patients who are taking or within two weeks from final taking of H2-receptor antagonists and Proton pump inhibitors 4.Patients who need of administration of proton pump inhibitors in urgently 5.Patients with serious liver failure or renal dysfunction 6.Patients who have hypersensitivity to Nexium10 Capsules 7.Patients who take Combination contraindicated drugs with Nexium10 Capsules(Atazanavir Sulfate,Rilpivirine Hydrochloride) 8.Patients who have Lactose intolerance 9.Patients who are judged as unsuitable for the study by the investigator for the other reasons
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method -DOPA blood concentration in blood collection point of before taking L-DOPA formulation and study drug, and after taking 10,20,30,45,60,90,120,240 minutes
- Secondary Outcome Measures
Name Time Method PDRS part3 Symptom diary